Navigation Links
Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease

WAYLAND, Mass., March 10, 2011 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease. This Phase I award provides Avaxia with approximately $145,000 in research and development funds. If early results are promising, the Company could receive an additional $1 million in Phase II funding.

"We are delighted to have been awarded this grant from the NIH in recognition of the potential of our novel approach to the treatment of celiac disease," said Barbara S. Fox, Ph.D., Avaxia's founder and CEO. "This NIH support provides the funding we need to advance the development of our anti-gluten antibody into pre-clinical models of celiac disease, which is a serious lifelong inherited autoimmune condition, affecting more than 2 million children and adults in the U.S. alone."

About Celiac Disease. Celiac disease is an inherited, autoimmune disease in which the lining of the small intestine is damaged from eating gluten and other proteins found in wheat, barley, rye, and possibly oats.  Celiac disease is also known as celiac sprue, nontropical sprue, and gluten-sensitive enteropathy.  The disease can develop at any point in life, from infancy to late adulthood.  The symptoms of celiac disease can vary significantly from person to person with the most common being abdominal bloating and pain, chronic diarrhea, vomiting, constipation and weight loss.  There is no medication available to treat the disease.  Patients must follow a lifelong gluten-free diet in an attempt to avoid symptoms.  More than 2 million people in the United States have the disease, or about 1 in 133 people.  

About Avaxia Biologics, Inc.:  Avaxia Biologics ( is an early stage company using its proprietary platform to develop orally-delivered antibody therapeutics to treat gastrointestinal disease. The antibodies are designed to address both diseases of the GI tract and systemic diseases where the disease targets are accessible in the GI tract. Avaxia's unique platform technology is supporting the rapid development of products for inflammatory bowel disease, acute radiation sickness, oral mucositis, celiac disease, diabetes and obesity.

SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
2. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
3. Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities, Trauma, and General Orthopaedics Market with Legato™ Bone Void Filler
4. DSM Biologics Reports a New Record Achievement with DSMs Proprietary XD® Process Technology with a CHO Cell Line Producing an Fc-fusion Protein:
5. MiMedx Completes Acquisition of Surgical Biologics
6. MiMedx Announces Agreement to Acquire Surgical Biologics
7. Amylin Submits Clinical and Nonclinical Sections of Rolling Biologics License Application for Metreleptin to Treat Rare Forms of Lipodystrophy
8. Reportlinker Adds Global Biosimilars (Follow-on biologics) Market: An Analysis
9. EUSA Pharma Submits ERWINASE(R) Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
10. Reportlinker Adds Quality for Biologics
11. Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
Post Your Comments:
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
Breaking Medicine Technology:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
Breaking Medicine News(10 mins):